Pathologic response prediction of survival aided by tumor type

Pathologic response prediction of survival aided by tumor type

(HealthDay) -- Pathologic complete response (pCR) is more highly predictive of recurrence-free survival (RFS) when specific breast cancer tumor type is factored in, according to a study published online May 29 in the Journal of Clinical Oncology.

To investigate the association between pCR and RFS overall and within receptor subsets, Laura J. Esserman, M.D., from the University of California at San Francisco, and colleagues assessed clinical, imaging, and from 221 patients with a tumor of ≥3 cm (median, 6.0 cm) who had received neoadjuvant chemotherapy.

The researchers found that, based on a 70-gene prognosis profile, 91 percent of participants were classified as poor risk. Of the participants, 41 percent were hormone receptor (HR) negative and 31 percent were human epidermal growth factor receptor 2 (HER2) positive. Among the 190 patients not treated with neoadjuvant trastuzumab, pCR was highest for patients with HR-negative/HER2-positive tumors (45 percent) and lowest for patients with HR-positive/HER2-negative tumors (9 percent). Achieving pCR was predictive of improved RFS. For 172 patients treated without trastuzumab, patients with pCR had a hazard ratio of 0.29 for RFS when compared to patients with no pCR. On multivariate analysis, when subtype was factored in, pCR was more predictive of RFS, with lower hazard ratios for HR-positive/HER2-negative (hazard ratio, 0.00), HR-negative/HER2-negative (hazard ratio, 0.25), and HER2-positive (hazard ratio, 0.14) subtypes. The predictive value of pCR within subsets was further improved with Ki67.

"pCR is more highly predictive of RFS within every established receptor subset than overall, demonstrating that the extent of outcome advantage conferred by pCR is specific to tumor biology," the authors write.

Several authors disclosed financial ties to the pharmaceutical and medical device industries.

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Generation of tanners see spike in deadly melanoma

5 hours ago

(AP)—Stop sunbathing and using indoor tanning beds, the acting U.S. surgeon general warned in a report released Tuesday that cites an alarming 200 percent jump in deadly melanoma cases since 1973.

Penn team makes cancer glow to improve surgical outcomes

5 hours ago

The best way to cure most cases of cancer is to surgically remove the tumor. The Achilles heel of this approach, however, is that the surgeon may fail to extract the entire tumor, leading to a local recurrence.

Cancer: Tumors absorb sugar for mobility

17 hours ago

Cancer cells are gluttons. We have long known that they monopolize large amounts of sugar. More recently, it became clear that some tumor cells are also characterized by a series of features such as mobility or unlikeliness ...

User comments